THERAPY DOSSIER · th-4fdceedd3b55

Anti-IL-15 neutralising antibody

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 7

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00433875 ↗PHASE2completed

Multiple Dose Treatment of Anti-IL-15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Enrolment: 180 · Results not recorded

NCT02637141 ↗PHASE2completed

Phase 2a Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease

Celiac Disease

Enrolment: 64 · Results not recorded

NCT02633020 ↗PHASE2completed

Phase 2a Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Type II Refractory Celiac Disease (RCD-II) · In-situ Small Bowel T-cell Lymphoma

Enrolment: 28 · Results not recorded

NCT00443326 ↗PHASE2completed

Ascending Dose Study to Evaluate Safety, Pharmacokinetics and Efficacy of AMG 714 in Subjects With Moderate to Severe Psoriasis

Psoriasis

Enrolment: 22 · Results not recorded

NCT04338581 ↗PHASE2completed

Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)

Vitiligo

Enrolment: 60 · Results not recorded

NCT04593251 ↗PHASE1completed

SAD and MAD Trial of CALY-002 (anti-IL-15 antibody) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Eosinophilic Esophagitis · Celiac Disease

Enrolment: 73 · Results not recorded

NCT03439475 ↗Phase not recordedno longer available

AMG 714 Expanded Access Program

Celiac Disease

Enrolment not recorded · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29959050 ↗2018Reported benefit

Interleukin 15 blockade protects the brain from cerebral ischemia-reperfusion injury.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6 (wild type and Il15 knockout)MaleAfter ischaemia-reperfusion

Model: Cerebral ischaemia-reperfusion (experimental ischaemic stroke)

Il15 knockout mice had smaller infarcts and fewer activated infiltrating lymphocytes. Post-ischaemia IL-15 blockade reduced infarct size, improved motor and locomotor activity and reduced effector function of NK, CD8 T and CD4 T cells.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…